Sequana Medical NV (2SE)

Overview

Sequana Medical NV is a pioneering medical device company focused on the development and commercialization of innovative treatments targeting fluid overload in critical conditions such as liver disease, cancer, and heart failure. The company, founded in 2006, has established a significant footprint in Belgium, Germany, France, Switzerland, and other international markets. Its corporate headquarters are stationed in Ghent, Belgium. Sequana Medical NV's mission revolves around improving patient quality of life and outcomes through its cutting-edge technology and solutions for managing fluid balance.

Products and Services

• alfapump System: An advanced, implantable pump system designed specifically for the automatic and continuous removal of ascites (abdominal fluid build-up) in patients suffering from refractory liver ascites and malignant ascites. This system offers a novel approach to managing ascites, reducing the need for frequent, invasive paracentesis procedures and thereby enhancing patient comfort and quality of life.
• Direct Sodium Removal (DSR): A ground-breaking therapy aimed at treating persistent congestion in heart failure patients by directly removing sodium from the body. This innovative treatment strategy addresses the underlying problem of sodium retention, a common issue in heart failure, potentially improving patient outcomes and reducing hospital readmissions related to heart failure exacerbations.
• alfapump DSR: A fully implanted system that combines the alfapump technology with Direct Sodium Removal therapy. The alfapump DSR system is specifically designed for heart failure patients with fluid overload, offering a comprehensive solution that targets the root causes of congestion by removing excess sodium and fluid from the body. This integrated approach represents a significant advancement in the management of fluid balance in heart failure patients, promising improved treatment efficacy and patient well-being.